Overview

A Phase 1, First-in-human Study of VX-634

Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-634 at various doses.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Criteria
Key Inclusion Criteria:

- Participants of age between 18 to 55 years (inclusive)

- Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m^2)

- A total body weight of more than (>)50 kg

- Participants of non childbearing potential

- Non smoker or ex-smoker for at least 3 months before screening

Key Exclusion Criteria:

- Any condition possibly affecting drug absorption

Other protocol defined Inclusion/Exclusion criteria may apply.